Johnson & Johnson (JNJ) says on track to become first healthcare company to exceed USD 100bln in annual revenue, with a clear line of sight to double-digit growth by the end of the decade

Johnson & Johnson's guidance to surpass USD 100 billion in annual revenue could signal strong growth prospects, especially with a projected boost in free cash flow to USD 21 billion by 2026.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

France has reportedly delayed the G7 meeting to discuss US tariff threats, according to Bloomberg; meeting has been pushed back to next week, citing WEF scheduling conflicts

[PREVIEW] Norges Bank policy announcement on 22nd January 2026

Johnson & Johnson (JNJ) says on track to become first healthcare company to exceed USD 100bln in annual revenue, with a clear line of sight to double-digit growth by the end of the decade

US President Trump says the US economy is booming and inflation has been defeated. Thinks the US will shortly see growth that "perhaps no country has ever seen before". European nations, Japan and South Korea are partners of the US.

Canadian PPI MoM (Dec) M/M -0.6% vs. Exp. 0.3% (Prev. 0.9%, Low. 0.1%, High. 0.5%)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Executive says expects to elevate free cash flow generation to approximately USD 21bln in 2026.
Context

This outlook may enhance investor confidence in the stock, positioning it favorably in the pharmaceutical space and potentially impacting sector dynamics as a notable trendsetter.

Related headlines

The whole workspace, free to try.

Try it free